We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
New women’s health biotech KaNDy Therapeutics—rumored to have attracted buyout interest from Allergan—has just reported data on its lead product that could enhance its allure.